Log In
Print
BCIQ
Print
Print this Print this
 

R256

  Manage Alerts
Collapse Summary General Information
Company Rigel Pharmaceuticals Inc.
DescriptionInhaled interleukin-13 (IL-13) signaling and JAK kinase (JAK) inhibitor
Molecular Target Interleukin-13 (IL-13) ; JAK kinase (JAK)
Mechanism of Action 
Latest Stage of DevelopmentPreclinical
IndicationAsthma
Partner

AstraZeneca plc
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today